<DOC>
	<DOCNO>NCT01133743</DOCNO>
	<brief_summary>This phase II , non-randomized , single institution study symptomatic , previously untreated CLL patient . All patient receive study drug , lenalidomide , give PO daily continuously 28 day cycle start dose level either 2.5 mg 5 mg dose escalation target dose 25mg daily . Oral dexamethasone 12 mg PO daily administer day 1-7 , 14 21 cycle . Patients treat lenalidomide dexamethasone 2 cycle past CR maximum 18 cycle , cycle 28 day duration . Primary endpoint response .</brief_summary>
	<brief_title>Open-Label Study Lenalidomide Combination With Oral Dexamethasone Treatment Previously Untreated , Symptomatic Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria 1 . Understand voluntarily sign informed consent form . 2 . Age &gt; /=18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . A confirmed diagnosis Bcell CLL IWCLL 2008 criterion 5 . No prior systemic therapy CLL . Steroid therapy alone autoimmune cytopenia ( anemia thrombocytopenia ) NOT consider prior systemic therapy . Radiation : Patients may receive prior radiation therapy restrict &lt; /= 25 % function bone marrow . Patients must &gt; /= 4 week since last treatment radiation therapy . Surgery : previous surgery permissible . Patient must &gt; /= 4 week since major surgery . 6 . Patients must symptomatic disease require therapy per IWCLL 2008 criterion . One follow must present eligible : Massive ( &gt; 10cm diameter ) , progressive symptomatic lymphadenopathy Massive ( &gt; 6 cm costal margin ) progressive symptomatic splenomegaly Anemia ( Hb &lt; 110 g/L ) Thrombocytopenia ( platelet &lt; 100 x 109/L ) Constitutional symptom ( one follow ) : Weight loss &gt; 10 % previous 6 month Significant fatigue Fevers &gt; 38 degree Celsius 2 week without infection Night sweat &gt; 1 month without evidence infection Other constitutional symptom felt require treatment per treat physician discretion Persistent rise lymphocyte count double time &lt; 6 month Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid standard therapy 7 . ECOG performance status &lt; /= 2 study entry 8 . Laboratory Requirements : ( must do within 7 day prior first study drug dose ) Hematology : Absolute granulocyte ( AGC ) &gt; /= 1000/mm³ Platelets &gt; /= 50,000/mm³ Chemistry : Creatinine clearance &gt; /= 30ml/min ( CockcroftGault calculation , see Appendix 9 ) Bilirubin &lt; /= 1.5 x UNL AST ( ALT AST available ) &lt; /= 2.5 x UNL 9 . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour start lenalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . 10 . Disease free prior malignancy &gt; /= 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast 11 . Able take aspirin 81 mg daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) . Exclusion criterion : Patients fulfill follow criterion eligible admission study : 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Evidence laboratory TLS CairoBishop Definition Tumor Lysis Syndrome . Subjects may enrol upon correction electrolyte abnormality . 5 . Use experimental drug therapy within 28 day baseline . 6 . Known hypersensitivity thalidomide . 7 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 8 . Any prior use lenalidomide . 9 . Concurrent use anticancer agent treatment . 10 . Known positive HIV infectious hepatitis , type B C. 11 . Known intolerance steroid ( i.e . poorly controllable hyperglycemia hypertension , significant mood disturbance , steroidrelated myopathy , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Immunomodulatory Drugs ( IMiD™ )</keyword>
	<keyword>Thalidomide analogue</keyword>
</DOC>